📊 CGON Key Takeaways
Is CG Oncology, Inc. (CGON) a Good Investment?
CG Oncology faces critical financial distress with annual operating cash burn of $57.2M against only $33.7M in cash reserves, yielding a runway of approximately 7 months at current burn rate. Minimal revenue of $1.1M is dwarfed by operating losses of $66.4M, indicating the company is not approaching profitability in any near-term scenario. Without immediate capital infusion or dramatic operational improvement, the company faces severe liquidity constraints.
CG Oncology shows very strong liquidity and a clean balance sheet, with $752.60M of equity, minimal long-term debt, and current/quick ratios above 24x, which gives it substantial financial flexibility. However, the business remains deeply unprofitable, with operating margin of -4722.1%, net margin of -3985.0%, and free cash flow of -$132.48M, so the core fundamental story still depends on converting early revenue growth into a scalable commercial base. The sharp revenue increase is encouraging, but growth quality remains unproven given the tiny revenue base relative to ongoing losses and cash burn.
CG Oncology, Inc. Key Strengths (CGON)
- Minimal debt leverage (0.00x Debt/Equity ratio) reduces financial obligations
- Strong balance sheet structure with $1.1B in total assets and low liabilities of $43.5M
- Exceptional current ratio of 31.3x and quick ratio of 31.25x on paper indicating short-term liquidity
- Exceptional balance sheet strength with very low leverage and large equity cushion
- Strong near-term liquidity, reducing immediate financing pressure
- Rapid year-over-year revenue growth suggests improving commercial traction
CGON Stock Risks: CG Oncology, Inc. Investment Risks
- Critical cash burn: Operating cash flow of -$56.9M annually against only $33.7M cash reserves (sub-7 month runway)
- Deeply unprofitable with net income of -$60.2M and net margin of -5558%, showing no path to near-term profitability
- Minimal revenue base of $1.1M cannot support current operating structure; massive operating losses of $66.4M indicate fundamental business model issues
- Extreme operating and net losses indicate the business model is not yet self-sustaining
- Heavy negative operating cash flow and free cash flow could erode liquidity over time
- Revenue remains too small relative to expense base, so current growth quality is still uncertain
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue growth trajectory and timeline to positive operating cash flow
- Capital raise announcements and debt issuance (funding urgency indicator)
- Quarterly revenue growth relative to operating expense growth
- Cash burn trajectory and ending cash balance
CG Oncology, Inc. (CGON) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 31.30x current ratio provides a solid financial cushion.
CGON Profit Margin, ROE & Profitability Analysis
CGON vs Healthcare Sector: How CG Oncology, Inc. Compares
How CG Oncology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CG Oncology, Inc. Stock Overvalued? CGON Valuation Analysis 2026
Based on fundamental analysis, CG Oncology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CG Oncology, Inc. Balance Sheet: CGON Debt, Cash & Liquidity
CGON Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CG Oncology, Inc.'s revenue has grown significantly by 255% over the 5-year period, indicating strong business expansion. The most recent EPS of $-15.65 indicates the company is currently unprofitable.
CGON Revenue Growth, EPS Growth & YoY Performance
CGON Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $52.0K | -$34.5M | $-0.45 |
| Q3 2025 | $43.0K | -$16.9M | $-0.30 |
| Q2 2025 | N/A | -$16.9M | $-0.28 |
| Q1 2025 | $52.0K | -$16.9M | $-0.36 |
| Q3 2024 | $9.0K | -$8.7M | $-0.30 |
| Q2 2024 | N/A | -$8.7M | $-0.28 |
| Q1 2024 | $194.0K | -$8.7M | $-0.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CG Oncology, Inc. Dividends, Buybacks & Capital Allocation
CGON SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CG Oncology, Inc. (CIK: 0001991792)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CGON
What is the AI rating for CGON?
CG Oncology, Inc. (CGON) has a Combined AI Grade of C from Claude (D) and ChatGPT (B) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CGON's key strengths?
Claude: Minimal debt leverage (0.00x Debt/Equity ratio) reduces financial obligations. Strong balance sheet structure with $1.1B in total assets and low liabilities of $43.5M. ChatGPT: Exceptional balance sheet strength with very low leverage and large equity cushion. Strong near-term liquidity, reducing immediate financing pressure.
What are the risks of investing in CGON?
Claude: Critical cash burn: Operating cash flow of -$56.9M annually against only $33.7M cash reserves (sub-7 month runway). Deeply unprofitable with net income of -$60.2M and net margin of -5558%, showing no path to near-term profitability. ChatGPT: Extreme operating and net losses indicate the business model is not yet self-sustaining. Heavy negative operating cash flow and free cash flow could erode liquidity over time.
What is CGON's revenue and growth?
CG Oncology, Inc. reported revenue of $1.1M.
Does CGON pay dividends?
CG Oncology, Inc. does not currently pay dividends.
Where can I find CGON SEC filings?
Official SEC filings for CG Oncology, Inc. (CIK: 0001991792) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CGON's EPS?
CG Oncology, Inc. has a diluted EPS of $-0.71.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CGON's fundamental grade?
Based on our AI fundamental analysis in June 2026, CG Oncology, Inc. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CGON stock overvalued or undervalued?
Valuation metrics for CGON: ROE of -5.5% (sector avg: 15%), net margin of -5,558.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CGON's AI grade for 2026?
Our dual AI analysis gives CG Oncology, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CGON's free cash flow?
CG Oncology, Inc.'s operating cash flow is $-56.9M, with capital expenditures of $304.0K. FCF margin is -5,286.0%.
How does CGON compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,558.8% (avg: 12%), ROE -5.5% (avg: 15%), current ratio 31.30 (avg: 2).